145 related articles for article (PubMed ID: 10586333)
1. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study.
Cripps C; Burnell M; Jolivet J; Batist G; Lofters W; Dancey J; Iglesias J; Fisher B; Eisenhauer EA
Ann Oncol; 1999 Oct; 10(10):1175-9. PubMed ID: 10586333
[TBL] [Abstract][Full Text] [Related]
2. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Eisenhauer E; Butts C; Gregg R; Dancey J; Fisher B; Iglesias J
J Clin Oncol; 1999 Apr; 17(4):1194. PubMed ID: 10561178
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Wu XY; Huang XE; You SX; Lu YY; Cao J; Liu J
Asian Pac J Cancer Prev; 2013; 14(3):2019-22. PubMed ID: 23679311
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.
Miller KD; Picus J; Blanke C; John W; Clark J; Shulman LN; Thornton D; Rowinsky E; Loehrer PJ
Ann Oncol; 2000 Jan; 11(1):101-3. PubMed ID: 10690396
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of pemetrexed in patients with metastatic renal cancer.
Thödtmann R; Sauter T; Weinknecht S; Weissbach L; Blatter J; Ohnmacht U; Hanauske A
Invest New Drugs; 2003 Aug; 21(3):353-8. PubMed ID: 14578684
[TBL] [Abstract][Full Text] [Related]
6. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study.
John W; Picus J; Blanke CD; Clark JW; Schulman LN; Rowinsky EK; Thornton DE; Loehrer PJ
Cancer; 2000 Apr; 88(8):1807-13. PubMed ID: 10760756
[TBL] [Abstract][Full Text] [Related]
7. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer.
Miles DW; Smith IE; Coleman RE; Calvert AH; Lind MJ
Eur J Cancer; 2001 Jul; 37(11):1366-71. PubMed ID: 11435066
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial.
Goedhals L; van Wiyk AL; Smith BL; Fourie SJ
Int J Gynecol Cancer; 2006; 16(3):1172-8. PubMed ID: 16803502
[TBL] [Abstract][Full Text] [Related]
10. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis.
Spielmann M; Martin M; Namer M; duBois A; Unger C; Dodwell DJ
Clin Breast Cancer; 2001 Apr; 2(1):47-51. PubMed ID: 11899382
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed in advanced colorectal cancer.
Louvet C; de Gramont A
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):56-62. PubMed ID: 15655939
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed in gastric cancer: clinical experience and future perspectives.
Celio L; Buzzoni R; Longarini R; Marchianò A; Bajetta E
Semin Oncol; 2002 Dec; 29(6 Suppl 18):63-8. PubMed ID: 12571814
[TBL] [Abstract][Full Text] [Related]
14. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
Rinaldi DA; Burris HA; Dorr FA; Woodworth JR; Kuhn JG; Eckardt JR; Rodriguez G; Corso SW; Fields SM; Langley C
J Clin Oncol; 1995 Nov; 13(11):2842-50. PubMed ID: 7595747
[TBL] [Abstract][Full Text] [Related]
15. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study.
Smit EF; Mattson K; von Pawel J; Manegold C; Clarke S; Postmus PE
Ann Oncol; 2003 Mar; 14(3):455-60. PubMed ID: 12598353
[TBL] [Abstract][Full Text] [Related]
16. Overview of phase I trials of multitargeted antifolate (MTA, LY231514).
Rinaldi DA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):82-8. PubMed ID: 10598560
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.
Clarke SJ; Abratt R; Goedhals L; Boyer MJ; Millward MJ; Ackland SP
Ann Oncol; 2002 May; 13(5):737-41. PubMed ID: 12075742
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.
Thödtmann R; Depenbrock H; Dumez H; Blatter J; Johnson RD; van Oosterom A; Hanauske AR
J Clin Oncol; 1999 Oct; 17(10):3009-16. PubMed ID: 10506594
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
Pivot X; Raymond E; Laguerre B; Degardin M; Cals L; Armand JP; Lefebvre JL; Gedouin D; Ripoche V; Kayitalire L; Niyikiza C; Johnson R; Latz J; Schneider M
Br J Cancer; 2001 Sep; 85(5):649-55. PubMed ID: 11531245
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.
O'Shaughnessy JA; Clark RS; Blum JL; Mennel RG; Snyder D; Ye Z; Liepa AM; Melemed AS; Yardley DA
Clin Breast Cancer; 2005 Jun; 6(2):143-9. PubMed ID: 16001992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
